A role for the androgen-receptor in clinically localized and advanced prostate cancer

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 2, 2008, Pages 357-372

  Mohler, James L ^a,b,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

androgen receptor; immunohistochemistry; prostate cancer; quantitative video image analysis

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; KI 67 ANTIGEN;

ACCURACY; ADVANCED CANCER; BASAL CELL; CANCER INHIBITION; CANCER LOCALIZATION; CANCER MORTALITY; CASTRATION; CONSENSUS DEVELOPMENT; EPITHELIUM CELL; FROZEN SECTION; GENE EXPRESSION REGULATION; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LETHALITY; PHENOTYPE; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; RECURRENT CANCER; REVIEW; SECRETORY CELL; STROMA; TRANSACTIVATION; TREATMENT RESPONSE;

DISEASE PROGRESSION; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STROMAL CELLS;

EID: 42949165515     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.01.009     Document Type: Review

References (76)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA: A Cancer Journal for Clinicians 57 (2007) 43-66
2. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 55 (2005) 74-108
3. Denmeade S.R., Lin X.S., and Isaacs J.T. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28 (1996) 251-265
4. Huggins C., and Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. The Journal of Urology 168 (2002) 9-12
5. Chang C.S., Kokontis J., and Liao S.T. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240 (1988) 324-326
6. Lubahn D.B., Joseph D.R., Sullivan P.M., et al. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240 (1988) 327-330
7. Lubahn D.B., Joseph D.R., Sar M., et al. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Molecular Endocrinology (Baltimore, Md.) 2 (1988) 1265-1275
8. Chang C., Chodak G., Sarac E., et al. Prostate androgen receptor: immunohistological localization and mRNA characterization. Journal of Steroid Biochemistry 34 (1989) 311-313
9. Bartsch W., Klein H., Schiemann U., et al. Enzymes of androgen formation and degradation in the human prostate. Annals of the New York Academy of Sciences 595 (1990) 53-66
10. Habib F.K., Odoma S., Busuttil A., et al. Androgen receptors in cancer of the prostate. Correlation with the stage and grade of the tumor. Cancer 57 (1986) 2351-2356
11. Masai M., Sumiya H., Akimoto S., et al. Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. Prostate 17 (1990) 293-300
12. Brendler C.B., Isaacs J.T., Follansbee A.L., et al. The use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate: a preliminary report. The Journal of Urology 131 (1984) 694-700
13. Benson Jr. R.C., Utz D.C., Holicky E., et al. Androgen receptor binding activity in human prostate cancer. Cancer 55 (1985) 382-388
14. Mohler J.L., Chen Y., Hamil K., et al. Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clinical Cancer Research 2 (1996) 889-895
15. Henshall S.M., Quinn D.I., Lee C.S., et al. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Research 61 (2001) 423-427
16. Kim D., Gregory C.W., Smith G.J., et al. Immunohistochemical quantitation of androgen receptor expression using color video image analysis. Cytometry 35 (1999) 2-10
17. Pertschuk L.P., Macchia R.J., Feldman J.G., et al. Immunocytochemical assay for androgen receptors in prostate cancer: a prospective study of 63 cases with long-term follow-up. Annals of surgical oncology 1 (1994) 495-503
18. Ricciardelli C., Choong C.S., Buchanan G., et al. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate 63 (2005) 19-28
19. Miyamoto K.K., McSherry S.A., Dent G.A., et al. Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. The Journal of Urology 149 (1993) 1015-1019
20. Zhang S.X., Bentel J.M., Ricciardelli C., et al. Immunolocalization of apolipoprotein D, androgen receptor and prostate specific antigen in early stage prostate cancers. The Journal of Urology 159 (1998) 548-554
21. Tilley W.D., Lim-Tio S.S., Horsfall D.J., et al. Detection of discrete androgen receptor epitopes in prostate cancer by immunostaining: measurement by color video image analysis. Cancer Research 54 (1994) 4096-4102
22. Chodak G.W., Kranc D.M., Puy L.A., et al. Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. The Journal of Urology 147 (1992) 798-803
23. de Winter J.A., Trapman J., Brinkmann A.O., et al. Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. The Journal of Pathology 160 (1990) 329-332
24. Pertschuk L.P., Schaeffer H., Feldman J.G., et al. Immunostaining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis. Laboratory Investigation 73 (1995) 302-305
25. Sadi M.V., and Barrack E.R. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer 71 (1993) 2574-2580
26. Grossfeld G.D., Hayward S.W., Tisty T.D., et al. The role of stroma in prostatic carcinogenesis. Endocrine-Related Cancer 5 (1998) 253-270
27. Thompson T.C., Timme T.L., Kadmon D., et al. Genetic predisposition and mesenchymal-epithelial interactions in ras+myc-induced carcinogenesis in reconstituted mouse prostate. Molecular Carcinogenesis 7 (1993) 165-179
28. Rowley D.R. What might a stromal response mean to prostate cancer progression?. Cancer Metastasis Reviews 17 (1998) 411-419
29. Arnold J.T., and Isaacs J.T. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocrine-Related Cancer 9 (2002) 61-73
30. Olapade-Olaopa E.O., MacKay E.H., Taub N.A., et al. Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. Clinical Cancer Research 5 (1999) 569-576
31. Guileyardo J.M., Johnson W.D., Welsh R.A., et al. Prevalence of latent prostate carcinoma in two U.S. populations. Journal of the National Cancer Institute 65 (1980) 311-316
32. Sakr W.A., Haas G.P., Cassin B.F., et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. The Journal of Urology 150 (1993) 379-385
33. Ries L.A., Wingo P.A., Miller D.S., et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 88 (2000) 2398-2424
34. Bouchardy C., Mirra A.P., Khlat M., et al. Ethnicity and cancer risk in Sao Paulo, Brazil. Cancer Epidemiology, Biomarkers and Prevention 1 (1991) 21-27
35. Gaston K.E., Kim D., Singh S., et al. Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. The Journal of Urology 170 (2003) 990-993
36. Li R., Wheeler T., Dai H., et al. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. American Journal of Surgical Pathology 28 (2004) 928-934
37. Pollack A., DeSilvio M., Khor L., et al. Ki-67 staining is a strong predictor of patient outcome for prostate cancer patients treated with androgen deprivation plus radiotherapy: An analysis of RTOG 92-02. International Journal of Radiation Oncology Biology Physics 57 suppl (2003) 200-201
38. Ricciardelli C, Jackson M, Choong C, et al. Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential. Prostate, in press.
39. Sadi M.V., Walsh P.C., and Barrack E.R. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 67 (1991) 3057-3064
40. Takeda H., Akakura K., Masai M., et al. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 77 (1996) 934-940
41. Prins G.S., Sklarew R.J., and Pertschuk L.P. Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. The Journal of Urology 159 (1998) 641-649
42. Nabi G., Seth A., Dinda A.K., et al. Computer based receptogram approach: an objective way of assessing immunohistochemistry of androgen receptor staining and its correlation with hormonal response in metastatic carcinoma of prostate. Journal of Clinical Pathology 57 (2004) 146-150
43. Mohler J.L., Gregory C.W., Ford III O.H., et al. The androgen axis in recurrent prostate cancer. Clinical Cancer Research 10 (2004) 440-448
44. van der Kwast T.H., Schalken J., Ruizeveld de Winter J.A., et al. Androgen receptors in endocrine-therapy-resistant human prostate cancer. International Journal of Cancer 48 (1991) 189-193
45. Visakorpi T., Hyytinen E., Koivisto P., et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics 9 (1995) 401-406
46. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nature Reviews. Cancer 1 (2001) 34-45
47. Gelmann E.P. Molecular biology of the androgen receptor. Journal of Clinical Oncology 20 (2002) 3001-3015
48. Grossmann M.E., Huang H., and Tindall D.J. Androgen receptor signaling in androgen-refractory prostate cancer. Journal of the National Cancer Institute 93 (2001) 1687-1697
49. Sadar M.D., Hussain M., and Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocrine-Related Cancer 6 (1999) 487-502
50. Klocker H., Eder I.E., Comuzzi B., et al. Androgen receptor function in prostate cancer progression. In: Chung L.W., Isaacs W.B., and Simons J.W. (Eds). Prostate cancer - biology, genetics, and the new therapeutics. 2nd ed. (2007), Humana Press, Totowa, NJ
51. Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Natural Medicines 10 (2004) 33-39
52. Taplin M.E., Bubley G.J., Shuster T.D., et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. The New England Journal of Medicine 332 (1995) 1393-1398
53. Taplin M.E., Bubley G.J., Ko Y.J., et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Research 59 (1999) 2511-2515
54. Linja M.J., Savinainen K.J., Saramaki O.R., et al. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Research 61 (2001) 3550-3555
55. Ford III O.H., Gregory C.W., Kim D., et al. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. The Journal of Urology 170 (2003) 1817-1821
56. Gregory C.W., Johnson Jr. R.T., Mohler J.L., et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Research 61 (2001) 2892-2898
57. Gregory C.W., He B., Johnson R.T., et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Research 61 (2001) 4315-4319
58. Agoulnik I.U., Vaid A., Nakka M., et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Research 66 (2006) 10594-10602
59. Guo Z., Dai B., Jiang T., et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10 (2006) 309-319
60. Mahajan N.P., Liu Y., Majumder S., et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proceedings of the National Academy of Sciences of the United States of America 104 (2007) 8438-8443
61. Shi S.R., Key M.E., and Kalra K.L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. The Journal of Histochemistry and Cytochemistry 39 (1991) 741-748
62. Kim D., Charlton J.D., Coggins J.M., et al. Semiautomated nuclear shape analysis of prostatic carcinoma and benign prostatic hyperplasia. Analytical and Quantitative Cytology and Histology 16 (1994) 400-414
63. Gaston K.E., Ford I.O., Singh S., et al. A novel method for the analysis of the androgen receptor. Current Urology Reports 3 (2002) 67-74
64. Kim D., Gregory C.W., French F.S., et al. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. The American Journal of Pathology 160 (2002) 219-226
65. Coggins J.M. Image and graphics library, object-oriented (IGLOO) manual (1993), Department of Computer Science, University of North Carolina, Chapel Hill, NC
66. Java Web Start Reference Manual. Available from:. http://java.sun.com/products/javawebstart/developers.htm
67. Roswell Park Cancer Institute Prostate Cancer Research. Available from:. http://www.roswellpark.org/Site/Research/Research_Programs/Prostate
68. Kim D. Multiscale image analysis of prostatic carcinoma and benign hyperplasia using confocal laser scanning microscope (1993), University of North Carolina
69. Pappolla M.A. Computerized image-analysis microspectroscopy of tissue sections. Archives of Pathology & Laboratory Medicine 112 (1988) 787-790
70. Mofidi R., Walsh R., Ridgway P.F., et al. Objective measurement of breast cancer oestrogen receptor status through digital image analysis. European Journal of Surgical Oncology 29 (2003) 20-24
71. Blatt R.J., Clark A.N., Courtney J., et al. Automated quantitative analysis of angiogenesis in the rat aorta model using Image-Pro Plus 4.1. Computer Methods and Programs in Biomedicine 75 (2004) 75-79
72. Cell analysis systems: Quantitative estrogen progestoerone user's manual, Application Version 2.0, Catalog Number 201325-00 (1990), Cell Analysis Systems, Inc, USA
73. ®. Information available from:. http://www.chromavision.com/product/acis.htm
74. Workstation AP. Information available from:. http://tripathimaging.com/nonus_ac_quic_immuno.htm
75. Otsu N. A threshold selection method from gray-level histograms. IEEE Transactions on Systems, Man, and Cybernetics 9 (1979) 62-66
76. In: Gonzalez R.C., and Woods R.E. (Eds). Digital image processing (1992), Addison-Wesley, Reading, MA 229-237